The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.

Yes, I am a US healthcare professional and would like to continue

Important Safety Information
Prescribing Information
TD-300 Instructions for Use
Patient Website

For the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Referral Form Request a Rep

Search

PAH
WHAT IS TYVASO?
EFFICACY & SAFETY
- TRIUMPH OLE
DOSING & TITRATION
PATIENT SUPPORT
CLINICIAN RESOURCES
REFERRAL FORM
REQUEST A REP
SEARCH

FOR US HEALTHCARE PROFESSIONALS ONLY

FULL PRESCRIBING INFORMATION

Site Map

Home
PAH
WHAT IS TYVASO?
EFFICACY & SAFETY
- TRIUMPH OLE
DOSING & TITRATION
PATIENT SUPPORT
CLINICIAN RESOURCES
REFERRAL FORM
REQUEST A REP
SEARCH

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension.
TYVASO inhibits platelet aggregation and increases the risk of bleeding.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension.
TYVASO inhibits platelet aggregation and increases the risk of bleeding.

Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both C_max and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.

DRUG INTERACTIONS/SPECIFIC POPULATIONS

The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both C_max and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
Safety and effectiveness in pediatric patients have not been established.
Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.

ADVERSE REACTIONS

Pulmonary Arterial Hypertension (WHO Group 1)

In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.

INDICATION

TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

Please see Full Prescribing Information, the TD-100 and TD-300 TYVASO^® Inhalation System Instructions for Use manuals, and other additional information at www.tyvaso.com or call 1‑877‑UNITHER (1-877-864-8437).

TYVISIhcpAPR2021(PAH)

WHO=World Health Organization

PAH
WHAT IS TYVASO?
EFFICACY & SAFETY
DOSING & TITRATION
PATIENT SUPPORT
CLINICIAN RESOURCES
REFERRAL FORM
REQUEST A REP
SEARCH
Request a Rep

PAH
WHAT IS TYVASO?
EFFICACY & SAFETY
DOSING & TITRATION

PATIENT SUPPORT
CLINICIAN RESOURCES
REFERRAL FORM
REQUEST A REP
Request a Rep

TYVASO FAQs
Important Safety Information
Full Prescribing Information
Drug Disposal Program
TD-300 Instructions for Use
Site Map
Contact Us
Privacy Policy
Terms of Use
About United Therapeutics

TYVASO is a registered trademark of United Therapeutics Corporation. All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.

©2021 United Therapeutics Corporation. All rights reserved. US/TYV/0516

This site is intended for use by US healthcare professionals only.